News
GlobalData on MSN16h
Dr. Falk Pharma’s PSC drug achieves endpoints in Phase III trialDr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback